Insmed Shareholders Approve Directors, Executive Pay and Auditor

The latest announcement is out from Insmed ( (INSM) ).

Insmed shareholders convened on May 13, 2026, for the company’s annual meeting, where they elected Elizabeth McKee Anderson and Clarissa Desjardins, Ph.D., as Class II directors to serve until the 2029 annual meeting, reaffirming the existing board composition and its oversight of the company’s strategy. Investors also backed, on a non-binding basis, the 2025 compensation package for Insmed’s named executive officers and ratified Ernst & Young LLP as independent auditor for the year ending December 31, 2026, signaling continued support for the firm’s executive pay practices and financial reporting framework.

The most recent analyst rating on (INSM) stock is a Buy with a $185.00 price target. To see the full list of analyst forecasts on Insmed stock, see the INSM Stock Forecast page.

Spark’s Take on INSM Stock

According to Spark, TipRanks’ AI Analyst, INSM is a Neutral.

The score is constrained primarily by weak financial quality—large operating losses and significant free-cash-flow burn—alongside a clearly bearish technical trend. These are partly offset by a constructive earnings call, with reiterated revenue guidance, strong BRINSUPRI launch execution, and an outlined path toward cash-flow positivity, but current profitability and momentum remain the dominant drags.

To see Spark’s full report on INSM stock, click here.

More about Insmed

Insmed Incorporated operates in the biopharmaceutical sector, focusing on the development and commercialization of therapies for serious and rare diseases. The company’s shareholder base and governance structure are key to supporting its long-term research, clinical development, and commercialization strategy in highly regulated and capital-intensive markets.

Average Trading Volume: 2,791,954

Technical Sentiment Signal: Hold

Current Market Cap: $25.06B

For an in-depth examination of INSM stock, go to TipRanks’ Overview page.